Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 76

Sort by

Sort Order Select

Journal Articles

Subsequent Treatment and Clinical Outcome Following Induction Therapy on a Phase II Study of Oral Azacitidine Plus CHOP for Peripheral T-Cell Lymphoma (PTCL)

Jia Ruan, Evelyn H. Orlando, Alison Moskowitz, Zhengming Chen, Neha Mehta-Shah, Lubomir Sokol, Steven Horwitz, Sarah C. Rutherford, Tejasvi Sahni, Ari M Melnick, Giorgio Inghirami, Leandro Cerchietti, John P. Leonard, Peter Martin

Blood (2024) 144 (Supplement 1): 1693.

https://doi.org/10.1182/blood-2024-206606

Published: 2024

Journal Articles

Genetic mechanisms underlying tumor microenvironment composition and function in diffuse large B-cell lymphoma

Leandro Cerchietti

Blood (2024) 143 (12): 1101–1111.

https://doi.org/10.1182/blood.2023021002

Published: 2024

Journal Articles

Qpctl Inhibition, By Targeting the Inflammatory Tumor Microenvironment, Constitutes a Novel Therapeutic Approach for Diffuse Large B-Cell Lymphoma

Nicolas Di Siervi, Jasper Mullender, María Victoria Revuelta, Nahuel Zamponi, Eloisi Caldas-Lopes, Yusuke Isshiki, Wendy BÃ©guelin, Marcel Scheepstra, Bastiaan Evers, Jens Wuerthner, Leandro Cerchietti

Blood (2023) 142 (Supplement 1): 49.

https://doi.org/10.1182/blood-2023-181264

Published: 2023

Journal Articles

Remodeling of the Immune Microenvironment By Oncogenic MYD88 Dictates Immunotherapy Responses across Indolent and Aggressive B-Cell Lymphomas

Jon Celay, Miriam Recalde, María Victoria Revuelta, Marta Larrayoz, Sara Rodriguez, Maria J Garcia-Barchino, Jennifer R. Chapman-Fredricks, Teresa Lozano, Juan J Lasarte, Ming Q. Du, Izidore S. Lossos, Sergio Roa, Aldo Roccaro, Miguel Canales, Felipe Prosper, Bruno Paiva, Leandro Cerchietti, Jose A. Martinez-Climent

Blood (2023) 142 (Supplement 1): 431.

https://doi.org/10.1182/blood-2023-173394

Published: 2023

Journal Articles

Multicenter phase 2 study of oral azacitidine (CC-486) plus CHOP as initial treatment for PTCL

Blood (2023) 141 (18): 2194–2205.

https://doi.org/10.1182/blood.2022018254

Published: 2023

Includes: Supplemental data

Journal Articles

Endothelial cell–leukemia interactions remodel drug responses, uncovering T-ALL vulnerabilities

Blood (2023) 141 (5): 503–518.

https://doi.org/10.1182/blood.2022015414

Published: 2023

Includes: Supplemental data

Journal Articles

FGFR1 Is a Novel Therapeutic Target in Relapsed/Refractory Diffuse Large B Cell Lymphoma (RR-DLBCL)

Nicolas Di Siervi, Maria Victoria Revuelta, Maria Teresa Cacciapuoti, Nahuel Zamponi, Rossella Marullo, Ari Melnick, Giorgio Inghirami, Leandro Cerchietti

Blood (2022) 140 (Supplement 1): 1322.

https://doi.org/10.1182/blood-2022-169529

Published: 2022

Journal Articles

Phase 1 study of oral azacitidine (CC-486) plus R-CHOP in previously untreated intermediate- to high-risk DLBCL

Peter Martin, Nancy L. Bartlett, Julio C. Chavez, John L. Reagan, Sonali M. Smith, Ann S. LaCasce, Jeffrey Jones, James Drew, Chengqing Wu, Erin Mulvey, Maria V. Revuelta, Leandro Cerchietti, John P. Leonard

Blood (2022) 139 (8): 1147–1159.

https://doi.org/10.1182/blood.2021011679

Published: 2022

Includes: Supplemental data

Journal Articles

A Predictive Endothelial-Leukemia Pre-Clinical Platform to Uncover Drug Vulnerabilities for Personalized Treatments

Blood (2021) 138 (Supplement 1): 704.

https://doi.org/10.1182/blood-2021-153300

Published: 2021

Journal Articles

Aging-Associated Epigenetic Reprogramming Alters the Germinal Center Reaction and Targets Pathways Related to Lymphomagenesis

Rossella Marullo, Maria Victoria Revuelta, Wendy Béguelin, Juan Lara-Garcia, Leandro Cerchietti

Blood (2021) 138 (Supplement 1): 676.

https://doi.org/10.1182/blood-2021-152684

Published: 2021

Journal Articles

Phase I Study of Oral Azacitidine (CC-486) Plus Salvage Chemotherapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Brian T. Hess, Leandro Cerchietti, Lindsey Hendrickson, Elizabeth Hill, Anshu Giri, Shanta Salzer, Sarah Hogan, Lacey Finch, Robin Klingenberg, Fang Hu, Nina D. Wagner-Johnston

Blood (2021) 138 (Supplement 1): 3567.

https://doi.org/10.1182/blood-2021-145493

Published: 2021

Journal Articles

S1918: A Phase II/III Randomized Study of R-Minichop with or without Oral Azacitidine (CC-486) in Participants Age 75 Years or Older with Newly Diagnosed Diffuse Large B Cell Lymphoma, Grade IIIb Follicular Lymphoma, Transformed Lymphoma, and High-Grade B-Cell Lymphomas with MYC and BCL2 and/or BCL6 Rearrangements

Elizabeth A Brem, Hongli Li, Anne W. Beaven, Paolo F. Caimi, Leandro Cerchietti, Ash A. Alizadeh, Rebecca L. Olin, Norah Lynn Henry, Hildy Dilon, Richard F. Little, Cara Laubach, Michael L. Leblanc, Jonathan W. Friedberg, Sonali M. Smith

Blood (2021) 138 (Supplement 1): 3565.

https://doi.org/10.1182/blood-2021-148193

Published: 2021

Journal Articles

High Rates of Remission with the Initial Treatment of Oral Azacitidine Plus CHOP for Peripheral T-Cell Lymphoma (PTCL): Clinical Outcomes and Biomarker Analysis of a Multi-Center Phase II Study

Blood (2021) 138 (Supplement 1): 138.

https://doi.org/10.1182/blood-2021-145495

Published: 2021

Journal Articles

A Phase I Study of Selinexor and R-ICE in Patients with Relapsed/Refractory Aggressive B-Cell Lymphomas

Blood (2020) 136 (Supplement 1): 7–8.

https://doi.org/10.1182/blood-2020-134699

Published: 2020

Journal Articles

XPO1 Relieves MYC-Induced Replication Stress Limiting the Immunogenicity of DLBCL Cells

Rossella Marullo, MDPhD, Maria Victoria Revuelta, PhD, Nahuel Zamponi, PhD, Sarah C. Rutherford, MD, Peter Martin, FRCPC, MD MS, Giorgio Inghirami, MD, John P. Leonard, MD, Leandro Cerchietti, MD

Blood (2020) 136 (Supplement 1): 18.

https://doi.org/10.1182/blood-2020-141464

Published: 2020

Journal Articles

Multi-Center Phase II Study of Oral Azacitidine (CC-486) Plus CHOP As Initial Treatment for Peripheral T-Cell Lymphoma (PTCL)

Jia Ruan, MD PhD, Alison J. Moskowitz, MD, Neha Mehta-Shah, MD, Lubomir Sokol, MD PhD, Zhengming Chen, PhD MPH, MS, Riyaad Rahim, Wei Song, Koen Van Besien, MD PhD, Steven M. Horwitz, MD, Sarah C. Rutherford, MD, Morton Coleman, MD FACP, Ari Melnick, MD, Giorgio Inghirami, MD, Leandro Cerchietti, MD, John P. Leonard, MD, Peter Martin, FRCPC, MD MS

Blood (2020) 136 (Supplement 1): 33–34.

https://doi.org/10.1182/blood-2020-136023

Published: 2020

Journal Articles

Microenvironmental Signatures Reveal Biological Subtypes of Diffuse Large B-Cell Lymphoma (DLBCL) Distinct from Tumor Cell Molecular Profiling

Leandro Cerchietti, MD, Giorgio Inghirami, MD, Nikita Kotlov, PhD, Viktor Svekolkin, PhD, Alexander Bagaev, PhD, Felix Frenkel, PhD, Maria Victoria Revuelta, PhD, Jude M Phillip, PhD, Maria Teresa Cacciapuoti, MS, Sarah C. Rutherford, MD, Peter Martin, FRCPC, MD MS, John P. Leonard, MD

Blood (2019) 134 (Supplement_1): 656.

https://doi.org/10.1182/blood-2019-128889

Published: 2019

Journal Articles

Heat Shock Factor 1 Reprograms the DLBCL Microenvironment to Evade Immune Surveillance and Support Tumor Growth

Jude M Phillip, DPhil, Maria Nieves Calvo Vidal, PhD, Maria Victoria Revuelta, PhD, Nahuel Zamponi, PhD, Stephen Sloan, Benet Pera Gresely, PhD, Tharu Fernando, PhD, Wayne Tam, MD PhD, Giorgio Inghirami, MD, Lawrence Bonassar, PhD, Ari M. Melnick, MD, Leandro Cerchietti, MD

Blood (2018) 132 (Supplement 1): 2854.

https://doi.org/10.1182/blood-2018-99-117774

Published: 2018

Journal Articles

Oral Azacitidine (CC-486) Plus R-CHOP in Patients with High-Risk or Previously Untreated Diffuse Large B-Cell Lymphoma, Grade 3B Follicular Lymphoma, or Transformed Lymphoma (AFT-08)

Peter Martin, FRCPC, MD MS, Nancy L. Bartlett, MD, Julio C. Chavez, MD, John L. Reagan, MD, Sonali M. Smith, MD, Ann S. LaCasce, MD MSc, Jeffrey A. Jones, MD MPH, James Drew, MA, Chengqing Wu, PhD, Leandro Cerchietti, MD, John P. Leonard, MD

Blood (2018) 132 (Supplement 1): 2964.

https://doi.org/10.1182/blood-2018-99-114438

Published: 2018

Journal Articles

Five-year follow-up of lenalidomide plus rituximab as initial treatment of mantle cell lymphoma

Jia Ruan, Peter Martin, Paul Christos, Leandro Cerchietti, Wayne Tam, Bijal Shah, Stephen J. Schuster, Amelyn Rodriguez, David Hyman, Maria Nieves Calvo-Vidal, Sonali M. Smith, Jakub Svoboda, Richard R. Furman, Morton Coleman, John P. Leonard

Blood (2018) 132 (19): 2016–2025.

https://doi.org/10.1182/blood-2018-07-859769

Published: 2018

NARROW

Subsequent Treatment and Clinical Outcome Following Induction Therapy on a Phase II Study of Oral Azacitidine Plus CHOP for Peripheral T-Cell Lymphoma (PTCL)

Genetic mechanisms underlying tumor microenvironment composition and function in diffuse large B-cell lymphoma

Qpctl Inhibition, By Targeting the Inflammatory Tumor Microenvironment, Constitutes a Novel Therapeutic Approach for Diffuse Large B-Cell Lymphoma

Remodeling of the Immune Microenvironment By Oncogenic MYD88 Dictates Immunotherapy Responses across Indolent and Aggressive B-Cell Lymphomas

Multicenter phase 2 study of oral azacitidine (CC-486) plus CHOP as initial treatment for PTCL

Endothelial cell–leukemia interactions remodel drug responses, uncovering T-ALL vulnerabilities

FGFR1 Is a Novel Therapeutic Target in Relapsed/Refractory Diffuse Large B Cell Lymphoma (RR-DLBCL)

Phase 1 study of oral azacitidine (CC-486) plus R-CHOP in previously untreated intermediate- to high-risk DLBCL

A Predictive Endothelial-Leukemia Pre-Clinical Platform to Uncover Drug Vulnerabilities for Personalized Treatments

Aging-Associated Epigenetic Reprogramming Alters the Germinal Center Reaction and Targets Pathways Related to Lymphomagenesis

Phase I Study of Oral Azacitidine (CC-486) Plus Salvage Chemotherapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

High Rates of Remission with the Initial Treatment of Oral Azacitidine Plus CHOP for Peripheral T-Cell Lymphoma (PTCL): Clinical Outcomes and Biomarker Analysis of a Multi-Center Phase II Study

A Phase I Study of Selinexor and R-ICE in Patients with Relapsed/Refractory Aggressive B-Cell Lymphomas

XPO1 Relieves MYC-Induced Replication Stress Limiting the Immunogenicity of DLBCL Cells

Multi-Center Phase II Study of Oral Azacitidine (CC-486) Plus CHOP As Initial Treatment for Peripheral T-Cell Lymphoma (PTCL)

Microenvironmental Signatures Reveal Biological Subtypes of Diffuse Large B-Cell Lymphoma (DLBCL) Distinct from Tumor Cell Molecular Profiling

Heat Shock Factor 1 Reprograms the DLBCL Microenvironment to Evade Immune Surveillance and Support Tumor Growth

Oral Azacitidine (CC-486) Plus R-CHOP in Patients with High-Risk or Previously Untreated Diffuse Large B-Cell Lymphoma, Grade 3B Follicular Lymphoma, or Transformed Lymphoma (AFT-08)

Five-year follow-up of lenalidomide plus rituximab as initial treatment of mantle cell lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only